Elizabeth S. Klings
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth S. Klings has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Harrison Farber
Division of Pulmonary, Sleep and Critical Care Medicine, Tufts Medical Center, Boston, Massachusetts
17 shared publications - Martin H. Steinberg
Division of Hematology and Medical Oncology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA
14 shared publications - Justin K. Lui
The Pulmonary Center, Boston University Chobanian and Avedisian School of Medicine Boston Massachusetts
7 shared publications - Kari R. Gillmeyer
VA Boston Healthcare System Center for Health Optimization and Implementation Research Boston, MA
7 shared publications - Paola Sebastiani
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
7 shared publications - Renda Soylemez Wiener
Center for Health Optimization & Implementation Research, VA Boston Healthcare System, Boston, MA, United States
7 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70382
Patterns and Trends in Vasoactive Medication Use in Patients With Pulmonary Arterial Hypertension Presenting With Shock
The optimal use of vasoactive medications in patients with pulmonary arterial hypertension with shock remains unknown. Using a national database, we benchmarked initial vasoactive practices. Twenty‐five distinct strategies were identified, most commonly norepinephrine, vasopressin, phenylephrine, and milrinone. Marked practice variation underscores clinical equipoise and the need for comparative effectiveness studies.
- 1 July 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (3) , e70382
Open AccessPatterns and Trends in Vasoactive Medication Use in Patients With Pulmonary Arterial Hypertension Presenting With Shock
The optimal use of vasoactive medications in patients with pulmonary arterial hypertension with shock remains unknown. Using a national database, we benchmarked initial vasoactive practices. Twenty‐five distinct strategies were identified, most commonly norepinephrine, vasopressin, phenylephrine, and milrinone. Marked practice variation underscores clinical equipoise and the need for comparative effectiveness studies.
- 30 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Risk stratifying systemic sclerosis–related pulmonary hypertension by left atrial strain
Objectives: The objective of the study was to explore left atrial (LA) strain, a quantitative index of left ventricular (LV) diastolic function, in risk stratifying patients with SSc-related pulmonary hypertension (SSc-PH). Methods: This was an exploratory, retrospective single-centre study of 124 patients with SSc-PH confirmed on right heart catheterization. We quantified and clustered the three components of LA global longitudinal strain (GLS): (i) reservoir (systole); (ii) conduit (early diastole); and (iii) contractile (late diastole), using echocardiograms closest to timing of right heart catheterization. We applied both the Kaplan–Meier method and a Cox proportional hazards model to determine associations with our primary outcome of all-cause mortality. Results: Using k-means clustering, we divided our cohort into three clusters: Cluster 1 (N = 40), Cluster 2 (N = 34) and Cluster 3 (N = 50). Compared with Cluster 1, Cluster 2 had the lowest median LA conduit strain, and Cluster 3 exhibited the lowest median LA contractile strain. There was a statistically significant difference in survival between clusters (log-rank P = 0.005). Median survival was 122.4 months, 67.9 months and 48.4 months for Cluster 1, Cluster 2 and Cluster 3, respectively. Compared with those in Cluster 1, patients in Cluster 2 and Cluster 3 had adjusted hazard ratios of 1.46 (95% CI: 0.71, 2.97) and 2.57 (95% CI: 1.32, 5.02) for all-cause mortality, respectively. Conclusion: Of the three LA GLS clusters, Cluster 3 had the shortest median survival. LA GLS may provide further risk stratification of patients with SSc-PH.
- 30 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Risk stratifying systemic sclerosis–related pulmonary hypertension by left atrial strain
Objectives: The objective of the study was to explore left atrial (LA) strain, a quantitative index of left ventricular (LV) diastolic function, in risk stratifying patients with SSc-related pulmonary hypertension (SSc-PH). Methods: This was an exploratory, retrospective single-centre study of 124 patients with SSc-PH confirmed on right heart catheterization. We quantified and clustered the three components of LA global longitudinal strain (GLS): (i) reservoir (systole); (ii) conduit (early diastole); and (iii) contractile (late diastole), using echocardiograms closest to timing of right heart catheterization. We applied both the Kaplan–Meier method and a Cox proportional hazards model to determine associations with our primary outcome of all-cause mortality. Results: Using k-means clustering, we divided our cohort into three clusters: Cluster 1 (N = 40), Cluster 2 (N = 34) and Cluster 3 (N = 50). Compared with Cluster 1, Cluster 2 had the lowest median LA conduit strain, and Cluster 3 exhibited the lowest median LA contractile strain. There was a statistically significant difference in survival between clusters (log-rank P = 0.005). Median survival was 122.4 months, 67.9 months and 48.4 months for Cluster 1, Cluster 2 and Cluster 3, respectively. Compared with those in Cluster 1, patients in Cluster 2 and Cluster 3 had adjusted hazard ratios of 1.46 (95% CI: 0.71, 2.97) and 2.57 (95% CI: 1.32, 5.02) for all-cause mortality, respectively. Conclusion: Of the three LA GLS clusters, Cluster 3 had the shortest median survival. LA GLS may provide further risk stratification of patients with SSc-PH.
- 23 January 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (3) , 369-378
Provider networks for pulmonary hypertension in Massachusetts: implications for improving referrals to expert care
Rationale: Despite clear guideline recommendations, few patients with pulmonary hypertension (PH) are referred to expert care, including high-risk patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Characterizing population-level care networks for patients with PH may inform understanding of referral patterns and help improve PH care quality. Objectives: We leveraged social network analysis to characterize existing provider networks for patients with PH and to identify provider-level factors associated with connections to PH experts. Methods: We linked patient-level data from the Massachusetts All-Payer Claims Database with provider-level data to identify all adults diagnosed with PH in 2014-2018 and all relevant providers who saw those patients for PH. We constructed provider networks among all patients with PH (“All-PH network”) and subsets of patients with risk factors for PAH or CTEPH (“PAH network” and “CTEPH network,” respectively). Our provider-level outcome was connection to PH experts, defined as sharing at least 1 patient with an expert. Within each network, we conducted multivariable regression models to determine the association between provider-level variables (specialty, practice location, PH panel volume) and our outcome. Results: We identified 4766 providers and 8970 patients with PH, of whom 1768 (19.7%) had PAH risk factors and 2164 (24.1%) had CTEPH risk factors. Few providers shared patients with PH experts (31% All-PH network, 35% PAH network, 19% CTEPH network). Within the All-PH network, primary care providers had 59% decreased odds of PH expert connection compared to nonexpert pulmonologists (adjusted odds ratio, 0.41 [95% confidence interval, 0.32-0.51]). Providers practicing outside the greater Boston area and those with smaller PH panel volumes were also less likely to be connected to a PH expert. Findings were similar among the PAH and CTEPH networks. Conclusions: We found significant gaps in connections to expert care, even among providers caring for patients at risk for PAH or CTEPH, which may be driven in part by limited provider experience, geographic barriers, and disconnected providers and care networks. Multifaceted strategies may be needed to improve referral rates for patients with PH.
- 23 January 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (3) , 369-378
Provider networks for pulmonary hypertension in Massachusetts: implications for improving referrals to expert care
Rationale: Despite clear guideline recommendations, few patients with pulmonary hypertension (PH) are referred to expert care, including high-risk patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Characterizing population-level care networks for patients with PH may inform understanding of referral patterns and help improve PH care quality. Objectives: We leveraged social network analysis to characterize existing provider networks for patients with PH and to identify provider-level factors associated with connections to PH experts. Methods: We linked patient-level data from the Massachusetts All-Payer Claims Database with provider-level data to identify all adults diagnosed with PH in 2014-2018 and all relevant providers who saw those patients for PH. We constructed provider networks among all patients with PH (“All-PH network”) and subsets of patients with risk factors for PAH or CTEPH (“PAH network” and “CTEPH network,” respectively). Our provider-level outcome was connection to PH experts, defined as sharing at least 1 patient with an expert. Within each network, we conducted multivariable regression models to determine the association between provider-level variables (specialty, practice location, PH panel volume) and our outcome. Results: We identified 4766 providers and 8970 patients with PH, of whom 1768 (19.7%) had PAH risk factors and 2164 (24.1%) had CTEPH risk factors. Few providers shared patients with PH experts (31% All-PH network, 35% PAH network, 19% CTEPH network). Within the All-PH network, primary care providers had 59% decreased odds of PH expert connection compared to nonexpert pulmonologists (adjusted odds ratio, 0.41 [95% confidence interval, 0.32-0.51]). Providers practicing outside the greater Boston area and those with smaller PH panel volumes were also less likely to be connected to a PH expert. Findings were similar among the PAH and CTEPH networks. Conclusions: We found significant gaps in connections to expert care, even among providers caring for patients at risk for PAH or CTEPH, which may be driven in part by limited provider experience, geographic barriers, and disconnected providers and care networks. Multifaceted strategies may be needed to improve referral rates for patients with PH.
- 1 June 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (6) , 838-845
Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension
Rationale: Guidelines recommend early referral to pulmonary hypertension experts for patients with confirmed or suspected pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), among others. Yet patients often have advanced disease at the time of referral. The drivers of these referral delays are not well known. Objectives: Building on our prior qualitative findings on barriers to timely pulmonary hypertension care along the care continuum, we sought to identify patient-level factors associated with referral to pulmonary hypertension experts. Methods: We leveraged the Massachusetts All-Payer Claims Database to identify all patients with incident pulmonary hypertension from 2015 to 2017 using a validated algorithm (sensitivity 28%, specificity 100%) and further identified subgroups with risk factors for PAH and CTEPH. Our outcome was the presence or absence of referral to a pulmonary hypertension expert during the study period. On the basis of our prior qualitative work, our three primary exposures were 1) Medicaid enrollment, 2) mental health diagnoses, and 3) distance to the nearest pulmonary hypertension center. We conducted separate multivariable logistic regression models to determine the association between each of our primary exposures and outcome, among our entire cohort and among those with risk factors for PAH and CTEPH. Results: Among our entire cohort (n = 12,505), 704 (5.6%) were seen by pulmonary hypertension experts. Among the subset with risk factors for PAH (n = 2,393) and CTEPH (n = 3,167), 242 (10.1%) and 185 (5.8%) were seen by pulmonary hypertension experts, respectively. Patients less likely to be referred included Medicaid recipients (adjusted odds ratio [aOR], 0.64 [95% confidence interval (CI), 0.53–0.77]), those with mental health diagnoses (aOR, 0.69 [95% CI, 0.58–0.83]), and those living further from a pulmonary hypertension center (aOR, 0.78 [95% CI, 0.74–0.82] for each 10-mile increase in distance to a pulmonary hypertension center). Findings were similar among those with risk factors for PAH and CTEPH. Conclusions: Few patients with pulmonary hypertension are referred to pulmonary hypertension experts, including those with risk factors for PAH and CTEPH. Factors associated with expert referral identified in this study highlight barriers to timely pulmonary hypertension care and offer targeted areas of future study to improve the timeliness of pulmonary hypertension care.
- 1 June 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (6) , 838-845
Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension
Rationale: Guidelines recommend early referral to pulmonary hypertension experts for patients with confirmed or suspected pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), among others. Yet patients often have advanced disease at the time of referral. The drivers of these referral delays are not well known. Objectives: Building on our prior qualitative findings on barriers to timely pulmonary hypertension care along the care continuum, we sought to identify patient-level factors associated with referral to pulmonary hypertension experts. Methods: We leveraged the Massachusetts All-Payer Claims Database to identify all patients with incident pulmonary hypertension from 2015 to 2017 using a validated algorithm (sensitivity 28%, specificity 100%) and further identified subgroups with risk factors for PAH and CTEPH. Our outcome was the presence or absence of referral to a pulmonary hypertension expert during the study period. On the basis of our prior qualitative work, our three primary exposures were 1) Medicaid enrollment, 2) mental health diagnoses, and 3) distance to the nearest pulmonary hypertension center. We conducted separate multivariable logistic regression models to determine the association between each of our primary exposures and outcome, among our entire cohort and among those with risk factors for PAH and CTEPH. Results: Among our entire cohort (n = 12,505), 704 (5.6%) were seen by pulmonary hypertension experts. Among the subset with risk factors for PAH (n = 2,393) and CTEPH (n = 3,167), 242 (10.1%) and 185 (5.8%) were seen by pulmonary hypertension experts, respectively. Patients less likely to be referred included Medicaid recipients (adjusted odds ratio [aOR], 0.64 [95% confidence interval (CI), 0.53–0.77]), those with mental health diagnoses (aOR, 0.69 [95% CI, 0.58–0.83]), and those living further from a pulmonary hypertension center (aOR, 0.78 [95% CI, 0.74–0.82] for each 10-mile increase in distance to a pulmonary hypertension center). Findings were similar among those with risk factors for PAH and CTEPH. Conclusions: Few patients with pulmonary hypertension are referred to pulmonary hypertension experts, including those with risk factors for PAH and CTEPH. Factors associated with expert referral identified in this study highlight barriers to timely pulmonary hypertension care and offer targeted areas of future study to improve the timeliness of pulmonary hypertension care.
- Open Access
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 689-690
Let’s Not Keep Acute Chest Syndrome Under an Umbrella
- 1 May 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (5) , 689-690
Open AccessLet’s Not Keep Acute Chest Syndrome Under an Umbrella
- Open Access
- 26 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (5) , 955-965
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment to a donor or no donor (SOC) arm based on the availability of an HLA-matched sibling or unrelated donor (BMT CTN 1503). A donor search was commenced after eligibility confirmation. The primary end point was a comparison of survival between the treatment arms 2 years after biologic assignment. Power calculations required 60 participants in the donor arm and 140 in the no donor arm to determine if early transplant-related mortality might be balanced by disease-related mortality over a longer period of follow-up. Secondary objectives were a comparison of the changes in SCD-related events, functional outcomes, and organ function. The data were analyzed according to the intent-to-treat principle. A total of 113 participants were enrolled with 28 in the donor arm and 85 in the no donor arm. The 2-year probabilities of survival were 89% and 93%, in the donor vs no donor arms. Vaso-occlusive pain (VOC) was less frequent in the donor arm in the second year after biologic assignment (P < .001). Based on PROMIS-57 surveys, there was a decrease in fatigue (P = .003) and an increase in the ability to participate in social roles and activities (P = .003) in the donor arm 2 years after biologic assignment. Differences in other secondary outcomes did not reach statistical significance. Barriers to accrual prevented an objective comparison of survival. Assignment to the donor arm led to improvements in VOC, fatigue, and social function. This trial was registered at www.clinicaltrials.gov as #NCT02766465.
- 26 February 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (5) , 955-965
Open AccessHematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment to a donor or no donor (SOC) arm based on the availability of an HLA-matched sibling or unrelated donor (BMT CTN 1503). A donor search was commenced after eligibility confirmation. The primary end point was a comparison of survival between the treatment arms 2 years after biologic assignment. Power calculations required 60 participants in the donor arm and 140 in the no donor arm to determine if early transplant-related mortality might be balanced by disease-related mortality over a longer period of follow-up. Secondary objectives were a comparison of the changes in SCD-related events, functional outcomes, and organ function. The data were analyzed according to the intent-to-treat principle. A total of 113 participants were enrolled with 28 in the donor arm and 85 in the no donor arm. The 2-year probabilities of survival were 89% and 93%, in the donor vs no donor arms. Vaso-occlusive pain (VOC) was less frequent in the donor arm in the second year after biologic assignment (P < .001). Based on PROMIS-57 surveys, there was a decrease in fatigue (P = .003) and an increase in the ability to participate in social roles and activities (P = .003) in the donor arm 2 years after biologic assignment. Differences in other secondary outcomes did not reach statistical significance. Barriers to accrual prevented an objective comparison of survival. Assignment to the donor arm led to improvements in VOC, fatigue, and social function. This trial was registered at www.clinicaltrials.gov as #NCT02766465.
- Open Access
- 1 January 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (1) , e70021
Contribution of QRS Prolongation to Transplant‐Free Survival in Sarcoidosis‐Related Pulmonary Hypertension
To study the contribution of QRS prolongation to transplant‐free survival, we conducted an observational study of 68 patients with sarcoidosis‐related pulmonary hypertension. Every 10‐ms increase in QRS interval was associated with an adjusted HR of 1.23 (95% CI: 1.06, 1.44) for the composite outcome of lung transplantation and all‐cause mortality.
- 1 January 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (1) , e70021
Open AccessContribution of QRS Prolongation to Transplant‐Free Survival in Sarcoidosis‐Related Pulmonary Hypertension
To study the contribution of QRS prolongation to transplant‐free survival, we conducted an observational study of 68 patients with sarcoidosis‐related pulmonary hypertension. Every 10‐ms increase in QRS interval was associated with an adjusted HR of 1.23 (95% CI: 1.06, 1.44) for the composite outcome of lung transplantation and all‐cause mortality.
- Open Access
- 1 January 2024
- Published by Wiley in Advances in Hematology
- Vol. 2024 (1) , 8838308
The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID‐19 Patients
Venous thromboembolism (VTE) risk is increased in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A key question was whether increased intensity of anticoagulation would help prevent VTE and improve patient outcomes, including transfer to the intensive care unit (ICU) and mortality. At the start of the coronavirus disease‐19 (COVID‐19) pandemic, our institution, Boston Medical Center, instituted a VTE risk stratification protocol based on patients’ initial D‐dimer levels, medical history, and presence of thrombosis to determine whether they should receive standard‐dose prophylaxis, high‐dose prophylaxis, or therapeutic anticoagulation. We performed a retrospective observational cohort study examining the association of degree of anticoagulation with outcomes in 915 hospitalized COVID‐19 patients hospitalized initially on the general inpatient wards between March 1,, 2020, and June 1, 2020. Patients directly hospitalized in the ICU were excluded. Most, 813 patients (89%), in our cohort were on standard‐dose prophylaxis; 32 patients (3.5%) received high‐dose prophylaxis; 70 patients (7.7%), were treated with therapeutic anticoagulation. VTE occurred in 45 patients (4.9%), and the overall in‐hospital mortality rate was 5.4% (49 deaths). On multivariable analysis of clinical outcomes in relation to type of anticoagulation, in the high‐dose prophylaxis group, there was a trend towards increased in‐hospital mortality (odds ratio 2.4 (0.8–7.5, 95% CI)) and increased ICU transfer (odds ratio 2.2 (0.9‐5.7, 95% CI)). Our results suggest that patients receiving high‐dose prophylaxis had more severe disease that was not mitigated by intermediate‐dose anticoagulation.
- 1 January 2024
- Published by Wiley in Advances in Hematology
- Vol. 2024 (1) , 8838308
Open AccessThe Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID‐19 Patients
Venous thromboembolism (VTE) risk is increased in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A key question was whether increased intensity of anticoagulation would help prevent VTE and improve patient outcomes, including transfer to the intensive care unit (ICU) and mortality. At the start of the coronavirus disease‐19 (COVID‐19) pandemic, our institution, Boston Medical Center, instituted a VTE risk stratification protocol based on patients’ initial D‐dimer levels, medical history, and presence of thrombosis to determine whether they should receive standard‐dose prophylaxis, high‐dose prophylaxis, or therapeutic anticoagulation. We performed a retrospective observational cohort study examining the association of degree of anticoagulation with outcomes in 915 hospitalized COVID‐19 patients hospitalized initially on the general inpatient wards between March 1,, 2020, and June 1, 2020. Patients directly hospitalized in the ICU were excluded. Most, 813 patients (89%), in our cohort were on standard‐dose prophylaxis; 32 patients (3.5%) received high‐dose prophylaxis; 70 patients (7.7%), were treated with therapeutic anticoagulation. VTE occurred in 45 patients (4.9%), and the overall in‐hospital mortality rate was 5.4% (49 deaths). On multivariable analysis of clinical outcomes in relation to type of anticoagulation, in the high‐dose prophylaxis group, there was a trend towards increased in‐hospital mortality (odds ratio 2.4 (0.8–7.5, 95% CI)) and increased ICU transfer (odds ratio 2.2 (0.9‐5.7, 95% CI)). Our results suggest that patients receiving high‐dose prophylaxis had more severe disease that was not mitigated by intermediate‐dose anticoagulation.
- 13 November 2023
- Published by Springer Nature in Lung
- Vol. 201 (6) , 565-569
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
- 13 November 2023
- Published by Springer Nature in Lung
- Vol. 201 (6) , 565-569
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.